Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma

References

• Vogt A, Schmid S, Heinimann K, et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017;2(2):e000172
   PubMed Web of Science ®Google Scholar
• Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604–616.
   PubMed Web of Science ®Google Scholar
• Pirani M, Marcheselli R, Marcheselli L, et al. Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. Ann Oncol. 2011;22(8):1845–1858.
   PubMed Web of Science ®Google Scholar
• Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(10):2208–2214.
   PubMed Web of Science ®Google Scholar
• Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol. 2006;24(10):1568–1574.
   PubMed Web of Science ®Google Scholar
• Chirieac LR, Barletta JA, Yeap BY, et al. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. J Cin Oncol. 2013;31(36):4544–4549.
   PubMed Web of Science ®Google Scholar
• Major A, Smith DE, Ghosh D, et al. Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis. Cancer. 2020;126(1):189–201.
   PubMed Web of Science ®Google Scholar
• Hemminki K, Lenner P, Sundquist J, et al. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol. 2008;26(11):1850–1857.
   PubMed Web of Science ®Google Scholar
• Landgren O, Pfeiffer RM, Stewart L, et al. Risk of second malignant neoplasms among lymphoma patients with a family history of cancer. Int J Cancer. 2007;120(5):1099–1102.
   PubMed Web of Science ®Google Scholar
• Herr MM, Schonfeld SJ, Dores GM, et al. Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes. Blood Adv. 2019;3(13):1961–1969.
   PubMed Web of Science ®Google Scholar
• Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Cin Oncol. 2010;28(33):4935–4944.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040–2045.
   PubMed Web of Science ®Google Scholar
• Srour SA, Li S, Popat UR, et al. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-Hodgkin lymphomas: long term results. Br J Haematol. 2017;178(4):561–570.
   PubMed Web of Science ®Google Scholar
• Tanba K, Chinen Y, Uchiyama H, et al. Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma. Blood Cancer J. 2018;8(1):1.
   PubMedGoogle Scholar
• International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993; 329(14):987–994.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• Rombouts AJM, Hugen N, van Beek JJP, et al. Does pelvic radiation increase rectal cancer incidence? - A systematic review and meta-analysis. Cancer Treat Rev. 2018;68:136–144.
   PubMed Web of Science ®Google Scholar
• Warren S, Gates O. Multiple primary malignant tumors. Survey of literature and statistical study. Am J Cancer. 1932;16:1358–1414.
   Google Scholar
• Howe HL. A review of the definition for multiple primary cancers in the United States in workshop proceedings from December 4–6, 2002. Princeton, NJ: North American Association of Central Cancer Registries; 2003.
   Google Scholar
• Hori M, Matsuda T, Shibata A, et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2015;45(9):884–891.
   PubMed Web of Science ®Google Scholar
• Jiang S, Zhen H, Jiang H. Second primary malignancy in diffuse large B-cell lymphoma patients: a SEER database analysis. Curr Probl Cancer. 2020;44(1):100502.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Marcheselli L, Bari A, et al. Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study. Haematologica. 2008;93(9):1335–1342.
   PubMed Web of Science ®Google Scholar
• André M, Mounier N, Leleu X, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004;103(4):1222–1228.
   PubMed Web of Science ®Google Scholar
• Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006;107(1):108–115.
   PubMed Web of Science ®Google Scholar
• Tao L, Clarke CA, Rosenberg AS, et al. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. Br J Haematol. 2017;178(1):72–80.
   PubMed Web of Science ®Google Scholar
• Okines A, Thomson CS, Radstone CR, et al. Second primary malignancies after treatment for malignant lymphoma. Br J Cancer. 2005;93(4):418–424.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Coiffier B. Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties. Clin Cancer Res. 2013;19(7):1660–1669.
   PubMed Web of Science ®Google Scholar
• Mounier N, Heutte N, Thieblemont C, et al. Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial. Clin Lymphoma Myeloma Leuk. 2012;12(3):151–154.
   PubMed Web of Science ®Google Scholar
• Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26–38.
   PubMed Web of Science ®Google Scholar
• Lambert R, Guilloux A, Oshima A, et al. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer. 2002;97(6):811–818.
   PubMed Web of Science ®Google Scholar
• Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94(3):182–192.
   PubMedGoogle Scholar
• Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst. 1995;87(7):524–530.
   PubMed Web of Science ®Google Scholar
• Tanimura A, Hirai R, Nakamura M, et al. The prognostic impact of dose-attenuated R-CHOP therapy for elderly patients with diffuse large B-cell lymphoma. Intern Med. 2018;57(24):3521–3528.
   PubMed Web of Science ®Google Scholar
• Inano S, Iwasaki M, Iwamoto Y, et al. Impact of high-dose chemotherapy and autologous transplantation as first-line therapy on the survival of high-risk diffuse large B cell lymphoma patients: a single-center study in Japan. Int J Hematol. 2014;99(2):162–168.
   PubMed Web of Science ®Google Scholar
• Myers RM, Hill BT, Shaw BE, et al. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large B-cell lymphoma. Cancer. 2018;124(4):816–825.
   PubMed Web of Science ®Google Scholar
• Thompson CA, Ghesquieres H, Maurer MJ, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014;32(31):3506–3512.
   PubMed Web of Science ®Google Scholar